PROCEPT BioRobotics (NASDAQ:PRCT) Trading 6.6% Higher – Time to Buy?

PROCEPT BioRobotics Corporation (NASDAQ:PRCT) shares rose 6.6% on Thursday . The company traded as high as $22.02 and last traded at $22.6570. 185,349 shares were traded during trading, a decline of 88% from the average session volume of 1,607,998 shares. The stock had previously closed at $21.25.

Key Stories Impacting PROCEPT BioRobotics

Here are the key news stories impacting PROCEPT BioRobotics this week:

• Neutral Sentiment: Multiple law firms are soliciting investors who purchased PROCEPT shares between February 28, 2024, and February 25, 2026, to seek lead-plaintiff status. The deadline is September 22, 2026. These notices are procedural and do not represent a finding that PROCEPT violated securities laws. Hagens Berman class-action notice
• Negative Sentiment: The lawsuit alleges that PROCEPT made misleading statements or omissions regarding demand for its Aquablation-related handpieces and the gap between handpiece sales and procedures. The complaints cite repeated sales underperformance, excess customer inventory and late-quarter bulk discounts that allegedly obscured underlying demand. The allegations also challenge explanations that revenue volatility was primarily caused by temporary saline shortages. Kahn Swick & Foti class-action notice
• Negative Sentiment: Law-firm releases reference an approximately 18% share-price decline tied to the alleged inventory issues and disclosures. Continued litigation could create legal expenses, potential settlement costs and reputational damage, while the underlying inventory buildup could weigh on future unit and handpiece sales. Investors should note that the complaints contain allegations rather than proven facts. SueWallSt investor notice

Analysts Set New Price Targets

Several research analysts recently issued reports on the company. Citigroup downgraded PROCEPT BioRobotics to a “hold” rating in a research report on Thursday, July 2nd. Wells Fargo & Company downgraded PROCEPT BioRobotics from an “overweight” rating to an “equal weight” rating and set a $19.00 price target for the company. in a research report on Wednesday, August 5th. Leerink Partners cut PROCEPT BioRobotics from an “outperform” rating to a “market perform” rating and cut their price target for the stock from $31.00 to $29.00 in a report on Thursday, June 11th. Evercore set a $23.00 price objective on PROCEPT BioRobotics in a research report on Wednesday, August 5th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of PROCEPT BioRobotics in a research note on Friday, July 17th. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, ten have issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $28.00.

PROCEPT BioRobotics Stock Down 1.4%

The company has a quick ratio of 5.35, a current ratio of 6.55 and a debt-to-equity ratio of 0.15. The firm has a market cap of $1.24 billion, a PE ratio of -11.16 and a beta of 0.89. The firm’s 50 day moving average is $21.06 and its 200-day moving average is $24.49.

PROCEPT BioRobotics (NASDAQ:PRCT) last announced its earnings results on Tuesday, August 4th. The company reported ($0.47) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.46) by ($0.01). The firm had revenue of $94.50 million for the quarter, compared to analyst estimates of $92.77 million. PROCEPT BioRobotics had a negative return on equity of 30.62% and a negative net margin of 32.53%.The firm’s revenue was up 19.3% compared to the same quarter last year. During the same quarter last year, the business posted ($0.35) EPS. As a group, equities research analysts expect that PROCEPT BioRobotics Corporation will post -1.67 earnings per share for the current fiscal year.

Insider Activity

In other PROCEPT BioRobotics news, CEO Larry L. Wood acquired 23,900 shares of the firm’s stock in a transaction dated Friday, August 7th. The shares were acquired at an average price of $20.85 per share, for a total transaction of $498,315.00. Following the completion of the acquisition, the chief executive officer directly owned 23,900 shares of the company’s stock, valued at $498,315. This trade represents a ? increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders sold a total of 1,000 shares of company stock worth $28,480 in the last 90 days. 4.00% of the stock is owned by company insiders.

Hedge Funds Weigh In On PROCEPT BioRobotics

Several large investors have recently added to or reduced their stakes in PRCT. BlackRock Inc. acquired a new stake in PROCEPT BioRobotics in the 2nd quarter worth about $109,961,000. Alliancebernstein L.P. increased its stake in shares of PROCEPT BioRobotics by 58.6% during the 3rd quarter. Alliancebernstein L.P. now owns 3,419,784 shares of the company’s stock valued at $122,052,000 after acquiring an additional 1,262,928 shares during the last quarter. T. Rowe Price Investment Management Inc. increased its stake in shares of PROCEPT BioRobotics by 59.4% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 3,271,408 shares of the company’s stock valued at $102,919,000 after acquiring an additional 1,218,815 shares during the last quarter. Mackenzie Financial Corp increased its stake in shares of PROCEPT BioRobotics by 8.2% during the 4th quarter. Mackenzie Financial Corp now owns 1,573,405 shares of the company’s stock valued at $49,512,000 after acquiring an additional 118,971 shares during the last quarter. Finally, Artisan Partners Limited Partnership lifted its holdings in shares of PROCEPT BioRobotics by 11.4% during the 4th quarter. Artisan Partners Limited Partnership now owns 1,520,700 shares of the company’s stock worth $47,841,000 after acquiring an additional 155,601 shares during the period. 89.46% of the stock is currently owned by hedge funds and other institutional investors.

PROCEPT BioRobotics Company Profile

PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company’s technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.

The company’s flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.